https://www.businesswire.com/news/home/20180820005366/en/Enigma-Biomedical-Group-Invicro-Sign-Collaboration-AgreementTORONTO–(BUSINESS WIRE)–Enigma Biomedical Group (EBG) today announced a collaboration agreement with Invicro, a Konica Minolta Company and a leading provider of imaging services and software for research and drug development, to work together on multiple projects, initially focusing on the enhancement of Invicro’s AmyloidIQ and TauIQ platforms. EBG will be responsible for providing data from their affiliate companies; Cerveau Technologies, Inc. and Meilleur Technologies, Inc.; novel Tau tracer (MK-6240) and Amyloid tracer (NAV-4694); respectively.
As part of the agreement, both parties will utilize the AmyloidIQ and TauIQplatforms to provide the pharmaceutical industry access to improved informatics and analytics capabilities together with a more streamlined approach to supporting neurodegenerative disease modifying therapy development.
Lee-Anne Gibbs, President of Enigma Biomedical Group said, “This is an important step in accelerating critical biomarker research projects globally and supporting our pharmaceutical partners efforts to combat neurodegenerative disease. Collaborating with Invicro’s IQ technology platform allows Enigma and our partners Cerveau and Meilleur, to continue to execute the collective strategy of providing biomarkers to industry and academics to accelerate research in the field of Neurodegenerative disease.”